StreetInsider.com News Articles

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 09 Mar 2026 16:01:00 -0400

BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to three newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of March 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 60,175 shares of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 09 Mar 2026 16:01:00 -0400

The inducement equity awards were granted effective as of March 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 60,175 shares of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 09 Mar 2026 16:01:00 -0400

The inducement equity awards were granted effective as of March 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 60,175 shares of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 09 Mar 2026 16:01:00 -0400

The inducement equity awards were granted effective as of March 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 60,175 shares of

Ocular Therapeutix (OCUL) PT Raised to $28 at Clear Street

Mon, 02 Mar 2026 16:01:13 -0400

Clear Street analyst Bill Maughan raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $28.00 (from $21.00) while maintaining a Buy rating.

The analyst comments "Ocular presented detailed data from the SOL-1 superiority trial in wet age-related macular degeneration (wAMD) at the Macula Society Annual Meeting and held an investor call this morning to discuss the results and several issues that were raised following the SOL-1 topline announcement on February 17th (see our note). Efficacy data was consistently positive, and bolstered the claim that AXPAXLI offers durable control of wAMD. Perhaps more importantly, discussion and context around floaters and cataracts

Ocular Therapeutix (OCUL) PT Raised to $28 at Clear Street

Mon, 02 Mar 2026 16:01:13 -0400

Clear Street analyst Bill Maughan raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $28.00 (from $21.00) while maintaining a Buy rating.

William Blair Reiterates Outperform Rating on Ocular Therapeutix (OCUL) following study results

Mon, 02 Mar 2026 10:19:27 -0400

William Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Ocular Therapeutix (NASDAQ: OCUL).

The analyst commented, "We believe the positive top-line results from SOL-1 validated the profile of Axpaxli as a durable and effective treatment for nAMD and likely other vascular retinal diseases, de-risked the ongoing SOL-R study that is expected to read out in first quarter 2027, and also de-risked its eventual approval. The company now plans to pursue an NDA submission in the near term. We are not yet updating our estimates to assume an early approval on a single study, but we do believe management has a

Form 8-K OCULAR THERAPEUTIX, INC For: Feb 27

Fri, 27 Feb 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260227/26081449.html

Form 8-K OCULAR THERAPEUTIX, INC For: Feb 27

Fri, 27 Feb 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260227/26081449.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 23 Filed by: Dugel Pravin

Wed, 25 Feb 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260225/26062055.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 23 Filed by: Dugel Pravin

Wed, 25 Feb 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260225/26062055.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 23 Filed by: Kaiser Peter

Wed, 25 Feb 2026 18:19:00 -0400

si-local-file:///var/storage/secattach/20260225/26062050.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 23 Filed by: Kaiser Peter

Wed, 25 Feb 2026 18:19:00 -0400

si-local-file:///var/storage/secattach/20260225/26062050.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 23 Filed by: Heier Jeffrey S.

Wed, 25 Feb 2026 18:18:00 -0400

si-local-file:///var/storage/secattach/20260225/26062049.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 23 Filed by: Heier Jeffrey S.

Wed, 25 Feb 2026 18:18:00 -0400

si-local-file:///var/storage/secattach/20260225/26062049.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 23 Filed by: Nayak Sanjay

Wed, 25 Feb 2026 18:17:00 -0400

si-local-file:///var/storage/secattach/20260225/26062033.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 23 Filed by: Nayak Sanjay

Wed, 25 Feb 2026 18:17:00 -0400

si-local-file:///var/storage/secattach/20260225/26062033.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 20 Filed by: Waheed Nadia

Tue, 24 Feb 2026 18:14:00 -0400

si-local-file:///var/storage/secattach/20260224/26053416.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 20 Filed by: Waheed Nadia

Tue, 24 Feb 2026 18:14:00 -0400

si-local-file:///var/storage/secattach/20260224/26053416.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 20 Filed by: LINDSTROM RICHARD L MD

Tue, 24 Feb 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260224/26053414.html

Form 4 OCULAR THERAPEUTIX, INC For: Feb 20 Filed by: LINDSTROM RICHARD L MD

Tue, 24 Feb 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260224/26053414.html

Ocular Therapeutix™ to Participate in March Investor Conferences

Tue, 24 Feb 2026 07:00:00 -0400

BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in several upcoming investor conferences in March 2026.

TD Cowen 46th Annual Health Care Conference:
Date: Monday, March 2, 2026
Fireside Chat: 9:10 – 9:40 AM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Boston, MA

Jefferies Biotech on the Beach Summit:
Date: Tuesday, March 10, 2026
Location: Miami, FL

Citizens Life Sciences Conference 2026:
Date: Wednesday, March 11, 2026
Fireside Chat: 9:00 – 9:25 AM ET
Presenter: Pravin

Ocular Therapeutix™ to Participate in March Investor Conferences

Tue, 24 Feb 2026 07:00:00 -0400

Jefferies Biotech on the Beach Summit:
Date: Tuesday, March 10, 2026
Location: Miami, FL

Citizens Life Sciences Conference 2026:
Date: Wednesday, March 11, 2026
Fireside Chat: 9:00 – 9:25 AM ET
Presenter: Pravin

Ocular Therapeutix™ to Participate in March Investor Conferences

Tue, 24 Feb 2026 07:00:00 -0400

Jefferies Biotech on the Beach Summit:
Date: Tuesday, March 10, 2026
Location: Miami, FL

Citizens Life Sciences Conference 2026:
Date: Wednesday, March 11, 2026
Fireside Chat: 9:00 – 9:25 AM ET
Presenter: Pravin

Ocular Therapeutix™ to Participate in March Investor Conferences

Tue, 24 Feb 2026 07:00:00 -0400

Jefferies Biotech on the Beach Summit:
Date: Tuesday, March 10, 2026
Location: Miami, FL

Citizens Life Sciences Conference 2026:
Date: Wednesday, March 11, 2026
Fireside Chat: 9:00 – 9:25 AM ET
Presenter: Pravin